Your browser doesn't support javascript.
loading
Efficacy of Nanofiber Sheets Incorporating Lenvatinib in a Hepatocellular Carcinoma Xenograft Model.
Yoshida, Terufumi; Kaibori, Masaki; Fujisawa, Nanami; Ishizuka, Mariko; Sumiyama, Fusao; Hatta, Masahiko; Kosaka, Hisashi; Matsui, Kosuke; Suzuki, Kensuke; Akama, Tomoya O; Katano, Tayo; Yoshii, Kengo; Ebara, Mitsuhiro; Sekimoto, Mitsugu.
Afiliación
  • Yoshida T; Department of Surgery, Kansai Medical University, 2-5-1 Shinmachi, Hirakata 573-1010, Japan.
  • Kaibori M; Department of Surgery, Kansai Medical University, 2-5-1 Shinmachi, Hirakata 573-1010, Japan.
  • Fujisawa N; Research Center for Functional Materials, National Institute for Materials Science (NIMS), Tsukuba 305-0044, Japan.
  • Ishizuka M; Department of Surgery, Kansai Medical University, 2-5-1 Shinmachi, Hirakata 573-1010, Japan.
  • Sumiyama F; Department of Surgery, Kansai Medical University, 2-5-1 Shinmachi, Hirakata 573-1010, Japan.
  • Hatta M; Department of Surgery, Kansai Medical University, 2-5-1 Shinmachi, Hirakata 573-1010, Japan.
  • Kosaka H; Department of Surgery, Kansai Medical University, 2-5-1 Shinmachi, Hirakata 573-1010, Japan.
  • Matsui K; Department of Surgery, Kansai Medical University, 2-5-1 Shinmachi, Hirakata 573-1010, Japan.
  • Suzuki K; Department of Otolaryngology, Head and Neck Surgery, Kansai Medical University, Hirakata 573-1010, Japan.
  • Akama TO; Department of Pharmacology, Kansai Medical University, Hirakata 573-1010, Japan.
  • Katano T; Department of Medical Chemistry, Kansai Medical University, Hirakata 573-1010, Japan.
  • Yoshii K; Department of Mathematics and Statistics in Medical Sciences, Kyoto Prefectural University of Medicine, Kyoto 606-0823, Japan.
  • Ebara M; Research Center for Functional Materials, National Institute for Materials Science (NIMS), Tsukuba 305-0044, Japan.
  • Sekimoto M; Department of Surgery, Kansai Medical University, 2-5-1 Shinmachi, Hirakata 573-1010, Japan.
Nanomaterials (Basel) ; 12(8)2022 Apr 15.
Article en En | MEDLINE | ID: mdl-35458072
Lenvatinib has a high response rate in unresectable advanced hepatocellular carcinoma (HCC). In this study, we investigated whether lenvatinib-incorporating poly(ε-caprolactone) sheets (lenvatinib sheets) as a drug delivery system (DDS) exerted antitumor effects in a murine HCC model. The lenvatinib sheets were designed for sustained release of approximately 1 mg lenvatinib for 14 days. For 14 days, 1 mg lenvatinib was orally administered to mice. Then, we compared the antitumor effects of lenvatinib sheets with those of oral lenvatinib. The tumor volume, body weight, and serum lenvatinib level were measured for 14 days. A peritoneal dissemination model was established to examine the survival prolongation effect of the lenvatinib sheets. Tumor growth was significantly inhibited in the lenvatinib sheet group compared with that in the no treatment and oral groups. The antitumor effect was significantly higher in the lenvatinib sheet group. Regardless of the insertion site, the serum lenvatinib levels were maintained and showed similar antitumor effects. The mitotic index was significantly inhibited in the lenvatinib sheet group compared with that in the control group. Furthermore, lenvatinib sheets improved the 30-day survival. Lenvatinib sheets showed sufficient antitumor effects and may serve as an effective novel DDS for advanced HCC.
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Nanomaterials (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Japón
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Nanomaterials (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Japón